Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00854360 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR
A Phase 2 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 487
- Enrollment target
NCT00854360 is a Phase 2 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 487 participants.
The verdict
NCT00854360, a Phase 2 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 487 participants
- Enrollment target
Study Summary
This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group, 2-week, multi-center, dose-range-finding study in male or female patients (12 years and older) with SAR.
Interventions
- DRUG Placebo
- DRUG Beclomethasone dipropionate HFA Nasal Aerosol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 487 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00854360
The ClinicalTrials.gov registry entry for NCT00854360 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 487 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00854360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00854360 about?
NCT00854360 is a clinical study titled "Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR". This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group, 2-week, multi-center, dose-range-finding study in male or female patients (12 years and older) with SAR.
What is the current status of trial NCT00854360?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 487 participants. The study started on 2009-03. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00854360?
The interventions under investigation include: Placebo (DRUG), Beclomethasone dipropionate HFA Nasal Aerosol (DRUG).
Who is sponsoring clinical trial NCT00854360?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.